Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

AbelZeta Receives FDA IND Clearance for Phase 1b/2 Clinical Trial of C-CAR168 in ...

14 September 2026 · By · Wire by Fusion42

Published

14 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at prnewswire.com →

◆ Verified

Fusion42 · 14 September 2026 · Fusion42 review

AbelZeta has received FDA Investigational New Drug (IND) clearance to begin a Phase 1b/2 clinical trial testing its C-CAR168 cell therapy in patients with progressive multiple sclerosis in the United States.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your biotech startup developing advanced cell therapies can now plan US market entry pathways with clearer regulatory precedence in neurodegenerative conditions. FDA IND clearance signals a smoother route for trials in progressive multiple sclerosis, a space ripe for innovative treatments.

◆ Coverage

1 source · 14 Sep 2026

◆ Related on Wire

◆ Topics

Biotechfda-indclinical-trialmultiple-sclerosiscell-therapyregulatory-approval